hit counter
Affimed N.V. (AFMD) Stock News Sentiment & Price - Sentifly
AFMD - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Affimed N.V. (AFMD)

Germany
Biotechnology
NASDAQ
AFMD Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AFMD Latest news
Seeking Alpha
Neutral
Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2021 Results - Earnings Call Transcript
2021-11-10 13:49

Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Affimed N.V. (AFMD) Reports Q3 Loss, Lags Revenue Estimates
2021-11-10 09:12

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -30.77% and -13.34%, respectively, for the quarter ended September 2021.

Benzinga
Neutral
Recap: Affimed Q3 Earnings
2021-11-10 08:01

Affimed (NASDAQ:AFMD) reported its Q3 earnings results on Wednesday, November 10, 2021 at 08:00 AM. Here's what investors need to know about the announcement.

GlobeNewsWire
Neutral
Affimed Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
2021-11-10 06:30

HEIDELBERG, Germany, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the quarter ended September 30, 2021, and provided an update on clinical and corporate progress.

GlobeNewsWire
Neutral
Affimed to Present at Upcoming Investor Conferences
2021-11-09 06:30

HEIDELBERG, Germany, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that management will present and host one-on-one meetings at the following investor conferences during the month of November 2021.

GlobeNewsWire
Neutral
Affimed and NKGen Biotech Announce Initiation of Patient Recruitment in a First-in-human Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Autologous NK Cell Product SNK01
2021-11-08 06:30

HEIDELBERG, Germany and SANTA ANA, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) and NKGen Biotech, both clinical stage biotech companies focused on harnessing the power of the body's innate immune system, announced today the initiation of patient recruitment in the open-label, multi-center phase 1/2a study (NCT05099549) evaluating the safety, tolerability, and anti-tumor activity of the innate cell engager (ICE®) AFM24 (Affimed's tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-binding ICE®) in combination with SNK01 (ex vivo expanded and activated autologous NK cell therapy from NKGen Biotech).

GlobeNewsWire
Neutral
Affimed Announces New Innate Cell Engager AFM28 Targeting CD123 to Treat Acute Myeloid Leukemia
2021-11-04 09:06

HEIDELBERG, Germany, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that AFM28, its novel Innate Cell Engager (ICE®), is designed to treat patients with Acute Myeloid Leukemia (AML) and other CD123+ myeloid malignancies, such as high-risk myelodysplastic syndrome (MDS).

GlobeNewsWire
Neutral
Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and Company-sponsored Event on AFM13
2021-11-04 09:05

HEIDELBERG, Germany, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will present two posters on its innate cell engagers (ICE®) at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH).

Zacks Investment Research
Positive
Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Should You Buy?
2021-11-03 16:05

Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire
Neutral
Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021
2021-10-29 06:30

HEIDELBERG, Germany, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release third quarter 2021 results on Wednesday, November 10, 2021, and host a conference call at 8:30 a.m. EST to discuss financial results and recent corporate developments.

Loading more news...